DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for oculocutaneous albinism type 1B — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOculocutaneous albinism type 1B maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for oculocutaneous albinism type 1b is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
In four Chinese families with oculocutaneous albinism, genetic analysis of the TYR and OCA2 genes identified compound heterozygous mutations in the TYR gene in three patients and heterozygous mutations in the OCA2 gene in one patient. Two novel TYR mutations, c.549_550delGT and c.1114delG, were reported. Heterozygous family members carrying the c.1114delG mutation in TYR or the c.1426A>G mutation in OCA2 presented with blond or brown hair and pale skin at birth, without ocular disorders, and their skin accumulated pigment over time and with sun exposure. The study did not test any drug or intervention.
A 2024 review states that current management of albinism is mainly supportive and focuses on optimising vision. It mentions emerging therapies with promising translational benefit but provides no drug names, trial results, or concrete efficacy data. A separate 2024 case report describes a single patient with oculocutaneous albinism type 1A and does not discuss any treatment.
No drug has been tested or shown to alter the course of oculocutaneous albinism type 1B in these abstracts. The genetic characterisation of partial phenotypes in heterozygous carriers suggests that some residual tyrosinase activity may be present, but no pharmacological attempt to increase that activity is reported. What is missing is any funded clinical trial of a repurposed or novel compound, a validated outcome measure for pigmentation or vision in this specific subtype, and patient stratification by the precise TYR mutation to identify who might have residual enzyme function to target.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of the European Academy of Dermatology and Venereology · 2003 · 75 citations
Oculocutaneous albinism
AbstractOculocutaneous albinism represents a group of inherited skin disorders characterized by a generalized reduction of cutaneous, ocular and pilar pigmentation from the time of birth. Oculocutaneous albinism types 1 and 2 are the most common, but several other types have been described. A defect in the melanin synthesis pathway, resulting in reduced formation of melanin, is responsible for oculocutaneous albinism. Aetiology, clinical manifestations, diagnosis and management are discussed.
Mutational Analysis of the TYR and OCA2 Genes in Four Chinese Families with Oculocutaneous Albinism
AbstractBACKGROUND: Oculocutaneous albinism (OCA) is an autosomal recessive disorder. The most common type OCA1 and OCA2 are caused by homozygous or compound heterozygous mutations in the tyrosinase gene (TYR) and OCA2 gene, respectively. OBJECTIVE: The purpose of this study was to evaluate the molecular basis of oculocutaneous albinism in four Chinese families. PATIENTS AND METHODS: Four non-consanguineous OCA families were included in the study. The TYR and OCA2 genes of all individuals were amplified by polymerase chain reaction (PCR), sequenced and compared with a reference database. RESULTS: Four patients with a diagnosis of oculocutaneous albinism, presented with milky skin, white or light brown hair and nystagmus. Genetic analyses demonstrated that patient A was compound heterozygous for c.1037-7T.A, c.1037-10_11delTT and c.1114delG mutations in the TYR gene; patient B was heterozygous for c.593C>T and c.1426A>G mutations in the OCA2 gene, patients C and D were compound heterozygous mutations in the TYR gene (c.549_550delGT and c.896G>A, c.832C>T and c.985T>C, respectively). The heterozygous c.549_550delGT and c.1114delG alleles in the TYR gene were two novel mutations. Interestingly, heterozygous members in these pedigrees who carried c.1114delG mutations in the TYR gene or c.1426A>G mutations in the OCA2 gene presented with blond or brown hair and pale skin, but no ocular disorders when they were born; the skin of these patients accumulated pigment over time and with sun exposure. CONCLUSION: This study expands the mutation spectrum of oculocutaneous albinism. It is the first time, to the best of our knowledge, to report that c.549_550delGT and c.1114delG mutations in the TYR gene were associated with OCA. The two mutations (c.1114delG in the TYR gene and c.1426A>G in the OCA2 gene) may be responsible for partial clinical manifestations of OCA.
Expert Review of Ophthalmology · 2024 · 5 citations · open access
Our current understanding of clinical characteristics and the genetics of patients with albinism
AbstractIntroduction Albinism is a heterogenous disease with variable phenotypic and genotypic presentations. Diagnosis can be challenging and clinical evaluation strategies vary.Areas covered This review examines the phenotypic and genotypic characteristics of albinism and discusses evaluation strategies used to assess its variable clinical presentations. Additionally, it explores the challenges faced by clinicians in diagnosing albinism and issues related to genetic testing, interpretation and subsequent counseling of affected patients and their families. It is important to note that although current management of albinism is mainly supportive and focuses on optimizing vision, there are emerging therapies with promising translational benefit.Expert opinion Ongoing research in the field of albinism is benefiting from recent advances, particularly in retinal imaging and phenotyping. Similarly, access to advanced technologies like next-generation and long-read sequencing has improved diagnostic accuracy for previous cases with missing heritability. Deeper genotyping and phenotyping as well as multicentre collaborative approaches have allowed better understanding of genotype-phenotype correlations. There is still a need for more research on the psychosocial aspects of albinism. Encouraging involvement of patients and the public in determining research priorities in this area is essential for a better understanding of the psychosocial impact on individuals with albinism.
AbstractImplication for health policy/practice/research/medical education: Oculocutaneous albinism may be similar to two related syndromes (Hermansky-Pudlak and Chediak-Higashi) and could lead to more widespread lysosome excretory defects. These defects could lead to accumulation of some intracellular material, leading to the gross discoloration of the kidney.
Yakut Medical Journal · 2024 · 0 citations · open access
A clinical case of albinism in a 12 year old child
AbstractThe article presents a clinical case of oculocutaneous albinism type 1A. The albinism type and concomitant diseases are determined. Oculocutaneous albinism is an inherited autosomal recessive disorder which is characterized by hypopigmentation of the skin and hair besides ocular albinism. Keywords: oculocutaneous albinism type 1A, reduced visual acuity, pigmentation, Yakutia, the Arctic
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
ALBINISM- A CONGENITAL DISORDER
AbstractABSTRACT Background: Albinism encompasses a group of inherited disorders characterized by reduced or absent melanin biosynthesis, affecting approximately 1 in 20,000 individuals worldwide with significant variability across geographical regions. These conditions present substantial clinical challenges and impact quality of life. Objective: This review aims to synthesize current understanding of albinism's genetic mechanisms, clinical manifestations, diagnostic approaches, available treatments, and emerging therapeutic strategies to provide a comprehensive framework for clinicians and researchers. Methods: A systematic literature search was conducted using PubMed, EMBASE, and Web of Science databases for articles published between 2000-2024, using keywords including "albinism," "oculocutaneous albinism," "ocular albinism," "melanin biosynthesis," "tyrosinase," and "albinism treatment." Studies were selected based on relevance, methodological rigor, and contribution to understanding albinism pathophysiology or treatment. Results: Recent advances have expanded understanding of albinism's genetic basis, with 22 genes now identified across various forms. Comprehensive phenotypic characterization has refined diagnostic approaches, while emerging therapies including gene-based interventions and repurposed pharmaceuticals show promise in preclinical studies. Conclusion: Albinism represents a paradigm for understanding melanin biology and neurodevelopmental visual pathways. While current management remains supportive, emerging molecular-based therapies may offer disease-modifying potential. Multidisciplinary approaches and increased awareness are essential to address both medical and psychosocial aspects of these conditions.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
